NHS England Low Priority Treatment Consultation - Aliskiren by all CCGs

Why it matters: NICE hypertension guidance states there is insufficient evidence of its effectiveness to determine its suitability for use in resistant hypertension. Whilst aliskiren has shown comparable efficacy to other antihypertensive agents in terms of blood pressure reduction, its effects on mortality and long-term morbidity are currently unknown.

This measure is currently under consultation. More details can be found on the NHS England website.

Description: Cost of Aliskiren per 1000 patients

CCGs are ordered by mean percentile over the past six months. Each chart shows the results for the individual CCG, plus deciles across all CCGs in the NHS in England.

---

Fetching data...